Company Reports Q4 Tangible Book Value Per Share of $37.59
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Reports Q4 tangible book value per share $37.59. Reports Q4 CET1 capital ratio 13.83%. "The quarter marked a return to profitability, supported by a lower provision expense as we continued to execute on credit risk reduction actions," said Susan Riel, president, and CEO of the company. "We are encouraged by our early progress and remain focused on our efforts to improve results. We will remain disciplined in executing on asset disposition strategies that are reducing exposures and improving overall credit quality."
Get Free Real-Time Notifications for Any Stock
Monitor tickers like EGBN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on EGBN
Wall Street analysts forecast EGBN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EGBN is 18.50 USD with a low forecast of 18.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 25.840
Low
18.00
Averages
18.50
High
19.00
Current: 25.840
Low
18.00
Averages
18.50
High
19.00
About EGBN
Eagle Bancorp, Inc. is a bank holding company for EagleBank (the Bank). The Bank is a chartered commercial bank. The Company, through the Bank, conducts a full-service community banking business in Northern Virginia, Suburban Maryland and Washington, D.C. The primary financial services offered by the Bank include real estate, commercial and consumer lending, as well as traditional deposit and repurchase agreement products. The Bank offers a range of commercial banking services to its business and professional clients, as well as consumer banking services to individuals living and/or working primarily in the Bank’s market area. The Bank’s loan portfolio consists of traditional business and real estate secured loans. It operates 12 branch offices: six in Suburban Maryland, three located in the District of Columbia, and three in Northern Virginia. It also has four lending centers and utilizes various digital capabilities, including remote deposit services and mobile banking services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eagle Bancorp (EGBN) Reports $7.6M Net Income in Q4 2025 with Improved Asset Quality
- Return to Profitability: Eagle Bancorp reported a net income of $7.6 million in Q4 2025, translating to $0.25 per share, a significant recovery from a $67.5 million loss in the previous quarter, which enhances investor confidence in the bank's financial health.
- Improved Asset Quality: Nonperforming loans declined to $106.8 million, down $12 million from the prior quarter, while special mention and substandard loans totaled $783.4 million, a reduction of $175.1 million, indicating effective measures taken to reduce risk and enhance asset quality.
- Funding Structure Optimization: In 2025, Eagle Bancorp successfully reduced brokered deposits by $602 million while increasing core deposits by $692 million, reflecting a proactive shift in funding management that supports future stability and profitability.
- Optimistic Outlook: The company forecasts a significant expansion in net interest margin for 2026, expected to range between 2.6% and 2.8%, with noninterest income projected to increase by 15% to 25%, demonstrating management's confidence in sustained performance improvements and strategic direction.
Continue Reading
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
- Sales Performance Miss: Abbott Laboratories reported Q4 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a 4.4% increase in sales but only 3% organic growth, indicating competitive pressure in the market.
- Earnings Outlook Disappointment: Although adjusted earnings per share of $1.50 met Wall Street expectations, the overall performance failed to boost investor confidence, resulting in a stock drop of over 7% on Thursday, reflecting concerns about future growth.
- Market Reaction Intense: Following Abbott's earnings report, the significant stock decline illustrates investor pessimism regarding the company's future performance, which may impact its market position in the MedTech sector.
- Industry Impact Significant: Abbott's disappointing results could trigger a ripple effect across the MedTech industry, prompting investors to reassess the financial health of other related companies, potentially leading to overall valuation fluctuations in the sector.
Continue Reading